Genfit Sa · EURONEXT:GNFT
Genfit Sa — Investor Presentation (April 2026)
17 slides from Genfit Sa's investor presentation, April 2026
Slide 1: Investor presentation
Investor presentation April 2026
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED B
Slide 3: Strategic Highlights and Value Drivers
Strategic Highlights and Value Drivers NEXT EXPECTED STEPS Ipsen’s Iqirvo® in PBC: Strong commercial sales1 trajectory 1 Major contributor to GENFIT’s financial strength (>US$200M first full year) Ipsen 1Q26 results (April 23, 2026) NASHnext® MASH Diagnostics: Upcoming momentum 2 Therapeutics market
Slide 4: Corporate Highlights
Corporate Highlights French biopharmaceutical company Listed on EURONEXT “GNFT” 4 growth drivers in addition to PBC 25+ years in liver diseases, taking + MASH Non-invasive diagnostic technology early assets to commercial stage1 + CCA Phase 2 (GNS561 combination) Catalysts + ACLF Phase 2 (G1090N/NTZ)
Slide 5: Solid Commercial Performance from Ipsen
1. PBC Solid Commercial Performance from Ipsen Iqirvo® sales (global, quarterly) since commercial launch1 €283,4M First full year net sales €78,8M €184M €204,6M Cumulative milestone payments received2 €76,6M €105.5M €128,0M €48,6M €79,4M €35,5M Cumulative royalties €43,9M received3 $23,3M €20,6M €14
Slide 6: Non-invasive diagnostic technology ideally positioned…
2. MASH Non-invasive diagnostic technology ideally positioned… LITMUS consortium (Europe) NIMBLE consortium (U.S.) Validation ROC curves of NIS4® vs NITs (N=702)1 † NIS recognized as best non- ‡ invasive technology to identify “at-risk” MASH patients Topline results from NIMBLE consortium, stage 1 (
Slide 7: …to address an important need, from diagnostics to monitoring
…to address an important need, from diagnostics to monitoring Highlights on potential Adressable adult population "AT RISK" MASH (U.S. only) Technology Diagnostic Monitoring Partners Timeline Obese ≈ 105–110 million LDT Labcorp as ≈ 42–43 % NASHnext® Reimbursement CDC, Adult Obesity Prevalence Maps
Slide 8: CCA with KRAS Mutation: A High Unmet Medical Need
3. CCA CCA with KRAS Mutation: A High Unmet Medical Need Rare and aggressive liver malignancy ~30% of patients with CCA harbor KRAS mutations4 that develops in the bile ducts • one of the most common genes that might be mutated or amplified resulting in the overactivation of some of these pathways5
Slide 9: Rationale for Combining Anticancer Therapies and GNS561
Rationale for Combining Anticancer Therapies and investigational drug GNS561, an Autophagy Inhibitor GNS561 PPT1 inhibitor in #1 Anticancer Therapies combination with a MEK inhibitor Oral #2 GNS561 Chemotherapeutic agents (Autophagy inhibitor) MAP Kinase pathway targeted therapies By entering the ly
Slide 10: Phase 1b: Highly Encouraging Early Data
Phase 1b: Highly Encouraging Early Data GNS561 PPT1 inhibitor in combination with a MEK inhibitor Oral Advanced KRAS-mutated cholangiocarcinoma remains a formidable clinical challenge, and the emerging activity seen in this initial study is encouraging. Because MEK inhibition alone has historically
Slide 11: Moving Forward
Moving Forward • Phase 1b dose escalation will continue as planned to confirm activity signal • 1H26 - Completion expected results will be used to establish recommended Phase 2 combination doses • 2H26 – targeted Phase 2 initiation Beyond CCA: a potential to explore the benefit of autophagy inhibiti
Slide 12: ACLF: A High Unmet Medical Need
4. ACLF ACLF: A High Unmet Medical Need CHRONIC PHASE ACUTE PHASE Acute Chronic Liver Disease Cirrhosis ACLF 23-74% mortality at 28 days Decompensation = UNDERLYING CONDITION = PRECIPITANT ≥ 1 ORGAN DYSFUNCTIONS/FAILURES ► NO APPROVED DRUGS Bacterial Alcohol Alcohol Viruses Kidney Cerebral Infection
Slide 13: Our Lead Asset in ACLF: G1090N/NTZ
Our Lead Asset in ACLF: G1090N/NTZ A Strong Scientific Rationale Findings to date: G1090N/NTZ ✓ Decreases systemic inflammation in animal models, including in ACLF models ✓ Protects liver, kidney & brain in rat models of ACLF by decreasing tissue damage Anti-inflammatory Oral ✓ Protects mice from mo
Slide 14: G1090N/NTZ's Potential Recently Confirmed in the Clinic
G1090N/NTZ’s Potential Recently Confirmed in the Clinic G1090N/NTZ Anti-inflammatory Oral The safety profile observed in Phase 1 and the consistent biological activity evidenced in ex vivo assays represent a meaningful step in development. These findings position G1090N as a promising candidate for
Slide 15: PSC: Ongoing Phase 3 Launched by Ipsen
5. PSC PSC: Ongoing Phase 3 Launched by Ipsen Click here for details on this trial (Ipsen’s 2025 Full‑Year Results) Click here for details on this trial (Ipsen’s 2025 Full-Year Results) In February 2026, Ipsen confirmed the initiation of the first and only global Phase 3 clinical trial, addressing a
Slide 16: Other R&D Programs
6. Other Other R&D Programs ACLF Continuum UCD/OA Research Collaboration with EVerZom1 SRT-015 CLM-022 VS-02-HE EViv VS-01-HAC Injectable Oral Injectable Peritoneal ASK1 NLRP3 inflammasome Urease Exosome Liposomal-based inhibitor inhibitor inhibitor Technology technology To inhibit apoptosis, To inh
Slide 17: Targeting Untapped Markets with High Potential
Potential Targeting Untapped Markets with High Potential ACLF 294,000 in 2021, US, EU4, UK | ~300,000 by 2036 ~$4Bn for grade 1-2 ACLF in US, EU4, UK by 2030 CCA 20,000 to 30,000 for US, EU4, UK ~$3.1Bn for US, EU4, UK UCD/OA 2,000 to 3,000 for US, EU4, UK ~$1.1Bn for US, EU4, UK PBC ~385,000 for Gl